![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NEK4 |
Gene summary for NEK4 |
![]() |
Gene information | Species | Human | Gene symbol | NEK4 | Gene ID | 6787 |
Gene name | NIMA related kinase 4 | |
Gene Alias | NRK2 | |
Cytomap | 3p21.1 | |
Gene Type | protein-coding | GO ID | GO:0000278 | UniProtAcc | P51957 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6787 | NEK4 | NAFLD1 | Human | Liver | NAFLD | 3.88e-03 | 2.74e-01 | -0.04 |
6787 | NEK4 | HCC1_Meng | Human | Liver | HCC | 1.59e-11 | -8.64e-02 | 0.0246 |
6787 | NEK4 | HCC1 | Human | Liver | HCC | 5.74e-04 | 2.93e+00 | 0.5336 |
6787 | NEK4 | HCC2 | Human | Liver | HCC | 1.10e-09 | 3.10e+00 | 0.5341 |
6787 | NEK4 | S014 | Human | Liver | HCC | 2.07e-04 | 2.89e-01 | 0.2254 |
6787 | NEK4 | S015 | Human | Liver | HCC | 4.22e-02 | 2.78e-01 | 0.2375 |
6787 | NEK4 | S016 | Human | Liver | HCC | 1.59e-03 | 2.42e-01 | 0.2243 |
6787 | NEK4 | S027 | Human | Liver | HCC | 5.21e-03 | 5.06e-01 | 0.2446 |
6787 | NEK4 | S028 | Human | Liver | HCC | 2.38e-14 | 6.82e-01 | 0.2503 |
6787 | NEK4 | S029 | Human | Liver | HCC | 7.26e-09 | 5.85e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00075687 | Liver | NAFLD | aging | 53/1882 | 339/18723 | 7.78e-04 | 9.77e-03 | 53 |
GO:20010206 | Liver | NAFLD | regulation of response to DNA damage stimulus | 36/1882 | 219/18723 | 2.14e-03 | 2.08e-02 | 36 |
GO:00075692 | Liver | NAFLD | cell aging | 23/1882 | 132/18723 | 6.18e-03 | 4.62e-02 | 23 |
GO:200102021 | Liver | HCC | regulation of response to DNA damage stimulus | 128/7958 | 219/18723 | 1.31e-06 | 1.90e-05 | 128 |
GO:000756822 | Liver | HCC | aging | 185/7958 | 339/18723 | 4.28e-06 | 5.50e-05 | 185 |
GO:00075691 | Liver | HCC | cell aging | 73/7958 | 132/18723 | 2.00e-03 | 1.01e-02 | 73 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NEK4 | SNV | Missense_Mutation | rs769037062 | c.1859G>A | p.Arg620Gln | p.R620Q | P51957 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-AX-A1C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NEK4 | SNV | Missense_Mutation | rs187332751 | c.2437N>T | p.Arg813Cys | p.R813C | P51957 | protein_coding | tolerated(0.13) | benign(0) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
NEK4 | SNV | Missense_Mutation | novel | c.1155G>T | p.Glu385Asp | p.E385D | P51957 | protein_coding | tolerated(0.39) | benign(0.001) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
NEK4 | SNV | Missense_Mutation | novel | c.1856N>T | p.Arg619Met | p.R619M | P51957 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A2HG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NEK4 | SNV | Missense_Mutation | novel | c.1102N>C | p.Asp368His | p.D368H | P51957 | protein_coding | deleterious(0) | possibly_damaging(0.789) | TCGA-AX-A2IO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
NEK4 | SNV | Missense_Mutation | rs755904931 | c.461G>C | p.Arg154Pro | p.R154P | P51957 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BK-A56F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NEK4 | SNV | Missense_Mutation | rs770689317 | c.2227C>T | p.Arg743Trp | p.R743W | P51957 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NEK4 | SNV | Missense_Mutation | novel | c.1006N>T | p.Gly336Cys | p.G336C | P51957 | protein_coding | tolerated(0.3) | benign(0.003) | TCGA-CC-A8HT-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
NEK4 | SNV | Missense_Mutation | novel | c.2325C>G | p.Ile775Met | p.I775M | P51957 | protein_coding | deleterious(0.04) | benign(0.346) | TCGA-49-AARO-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
NEK4 | SNV | Missense_Mutation | novel | c.485N>C | p.Met162Thr | p.M162T | P51957 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-55-7576-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | alimta | CR |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6787 | NEK4 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | TAMATINIB | R-406 | ||
6787 | NEK4 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | DOVITINIB | DOVITINIB | ||
6787 | NEK4 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | BAY-613606 | CHEMBL541400 | ||
6787 | NEK4 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | GW441756X | GW441756X | ||
6787 | NEK4 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | TAE-684 | TAE-684 | ||
6787 | NEK4 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | SNS-314 | SNS-314 | ||
6787 | NEK4 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | CENISERTIB | CENISERTIB | ||
6787 | NEK4 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | CYC-116 | CYC-116 | ||
6787 | NEK4 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | PHA-767491 | CHEMBL225519 | ||
6787 | NEK4 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | SP-600125 | SP-600125 |
Page: 1 2 |